GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Material
Language
  • 1
    In: European Heart Journal, Oxford University Press (OUP), Vol. 36, No. 15 ( 2015-04-14), p. 915-923
    Type of Medium: Online Resource
    ISSN: 1522-9645 , 0195-668X
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2015
    detail.hit.zdb_id: 2001908-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Japanese Journal of Clinical Oncology, Oxford University Press (OUP), Vol. 43, No. 2 ( 2013-02-01), p. 208-213
    Type of Medium: Online Resource
    ISSN: 0368-2811 , 1465-3621
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2013
    detail.hit.zdb_id: 1494610-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2012
    In:  European Heart Journal Vol. 33, No. suppl 1 ( 2012-08-02), p. 339-653
    In: European Heart Journal, Oxford University Press (OUP), Vol. 33, No. suppl 1 ( 2012-08-02), p. 339-653
    Type of Medium: Online Resource
    ISSN: 0195-668X , 1522-9645
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2012
    detail.hit.zdb_id: 2001908-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Phytoparasitica, Springer Science and Business Media LLC, Vol. 16, No. 2 ( 1988-6), p. 179-213
    Type of Medium: Online Resource
    ISSN: 0334-2123 , 1876-7184
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 1988
    detail.hit.zdb_id: 1469840-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2010
    In:  Japanese Journal of Clinical Oncology Vol. 40, No. 10 ( 2010-10-01), p. 905-912
    In: Japanese Journal of Clinical Oncology, Oxford University Press (OUP), Vol. 40, No. 10 ( 2010-10-01), p. 905-912
    Type of Medium: Online Resource
    ISSN: 0368-2811 , 1465-3621
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2010
    detail.hit.zdb_id: 1494610-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: The Breast, Elsevier BV, Vol. 20 ( 2011-03), p. S33-
    Type of Medium: Online Resource
    ISSN: 0960-9776
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2011
    detail.hit.zdb_id: 2009043-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2010
    In:  Cancer Research Vol. 70, No. 24_Supplement ( 2010-12-15), p. P1-02-01-P1-02-01
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 70, No. 24_Supplement ( 2010-12-15), p. P1-02-01-P1-02-01
    Abstract: Background: Vasohibin-1 is a recently identified negative feedback regulator of angiogenesis induced by vascular endothelial growth factor (VEGF)-A. This is the first study to evaluate immunoreactivity and mRNA expression of Vasohibin-1 in human breast disorders. Material and Methods: We examined 251 breast specimens including invasive ductal carcinoma (IDC: 148), ductal carcinoma in situ (DCIS:62), fibroadenoma (FA:16), inflammatory lesion (6), fibrocystic change(9) and non-pathological breast tissue(7). We immunolocalized vasohibin-1 and compared its immunoreactivity to that of VEGF-A, VEGF receptor 2 (Flk-1), CD31 and Ki-67. The correlation of vasohibin-1 immunoreactibity with overall survival (OS), and disease free survival (DFS) of the breast carcinoma patients was also evaluated. In addition, we evaluated Ki-67 and CD31, and Ki-67 and vasohibin-1 double-immunostaining for further characterization of neovascularization. We also evaluated mRNA expression of Vasohibin-1 using a real-time quantitative RT-PCR with LightCycler system. Results: Vasohibin-1 was detected in endothelial cells of human breast and its immunodensity was significantly higher in IDC and inflammatory lesion than the other types (P & lt;0.001). As for DCIS, there was a significant positive correlation between vasohibin-1 expression level and nuclear grade or Van Nuys classification of carcinoma cells (P & lt;0.001). In addition, a significant positive correlation was detected between vasohibin-1 and VEGF-A, Flk-1 or Ki-67 (P & lt;0.001). There was also positive associations between vasohibin-1 and OS (P=0.004) and DFS (P & lt;0.001). Results of double-immunostaining demonstrated the ratio of Ki-67-positive cells among vasohibin-1-positive endothelial cells (46.5%) was significantly higher than those among CD31-positive cells (23.5%). In addition, there was a significant positive correlation between Vasohibin-1 mRNA level and Ki-67 or high nuclear grade(P & lt;0.001). Discussion: This is the first study demonstrating the status of vasohibin-1 in human breast lesions, which indicates that vasohibin-1 is associated with neovascularization and may especially play important roles in the regulation of intratumoral angiogenesis in human breast cancer. Vasohibin-1 is supposed to be induced in the downstream of VEGF-A/Flk-1 signaling pathway and considered an appropriate biomarker for intratumoral neovascularization. In addition, these results clearly indicated that vasohibin-1 expression may become one of the prognostic markers for metastasis and prognosis, and also become one of the appropriate biomarker of the potential of subsequent stromal invasion of carcinoma cells. Figures available in online version. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-02-01.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2010
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2016
    In:  Cancer Research Vol. 76, No. 4_Supplement ( 2016-02-15), p. P1-10-29-P1-10-29
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 76, No. 4_Supplement ( 2016-02-15), p. P1-10-29-P1-10-29
    Abstract: PURPOSE: The aromatherapy has been performed as palliative care of the breast cancer patients but no studies have been reported regarding whether the therapy improved QOL of the patients during perioperative periods or not. Therefore, in this study, we compared the effects on QOL between aromatherapy and conventional therapy during perioperative periods of the patients. METHODS: We examined Japanese breast cancer patients operated at Nahanishi Clinic , Okinawa, JAPAN.The patients were randomly assigned to a 2:1 ratio to aromatherapy or usual care following the informed consents were obtained. The aromatherapy group had aroma-oil (lavender, orange or ylang-ylang) placed at the bedside from 9 pm until 6 am. QOL of the patients was the primary endpoints and the changes of vital signs and the rate of hypnotic usage as secondary endpoints. QOL was assessed using the EORTC QLQ-C30,in which the Patients completed a baseline QOL assessment at the time of admission , of surgery day (AM7:00) and at the morning of post-operative day 1. Vital signs and hypnotic usage were also recorded at the same time. RESULTS: Among 249 women screened, we randomized 153 women, with 102 to aromatherapy and 51 to conventional care. QOL tended to be improved among aromatherapy groups in physical functioning and role functioning at the morning of post-operative day 1, but the differences did not reach statistical significance (P = 0.08 and 0.09, respectively). There were no statistically significant differences between two groups in the other points of QOL assessment. Aromatherapy did by no means improve vital signs and the rate of hypnotic usage of the patients. Global health status, functional scales and symptomatic scales of aromatherapy and usual care assessed by the EORTC QLQ-C30 questionnaire Aromatherapy  Usual care   (%)Good (≥66.7)Average (33.3-66.6)Poor ( & lt;33.3)Good (≥66.7)Average (33.3-66.6)Poor ( & lt;33.3)PAfter operation       Global health status       QOL47.143.19.833.352.913.7.26Functional scales       Physical functioning76.518.64.958.831.49.8.08Role functioning81.48.89.870.621.67.8.09Emotional functioning81.416.71.976.519.63.9.68Congnitive functionin85.313.71.090.27.82.0.51Social functioning82.412.74.968.619.611.8.13Symptom scales/items       Fatigue10.856.932.415.758.825.5.56Nausea and vomiting2.922.574.52.013.784.3.39Pain11.853.934.319.649.031.4.43Dyspnoea3.927.568.65.933.360.8.61Insomnia22.548.029.435.339.225.5.24Appetite loss8.839.252.07.839.252.9.98Constipation8.834.356.99.837.352.9.90Diarrhoea1.08.890.23.93.992.2.27Financial functioning16.742.241.225.535.339.2.41 Conclusion: Aromatherapy did not improve the QOL including vital signs and the rate of hypnotic usage during perioperative periods but no adverse effects also detected. Therefore, aromatherapy may not be prohibited during perioperative periods of the patients when they asked to the physicians. Citation Format: Tamaki K, Komatsu-Fukuyama A, Terukina S, Kamada Y, Uehara K, Yamashiro K, Arakaki M, Miyashita M, Ishida T, Ohuchi N, Sasano H, Tamaki N. Randomized trial of aromatherapy vs. conventional care for breast cancer patients during perioperative periods. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-10-29.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2016
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 78, No. 4_Supplement ( 2018-02-15), p. P6-11-01-P6-11-01
    Abstract: Aromatase inhibitors (AIs) have been used in the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer as a consequence of the significant benefit in DFS and OS when compared with tamoxifen. However the patients who receive AIs have an increased risk of arthralgia, at most 50% of patients did not take AIs and the 20% of the discontinued patients were within the first year of use. The HOPE study demonstrated that exercise was effective in improving AI-induced arthralgia. We conducted the AIAI (Arthralgia Improvement for the patients with Aromatase Inhibitors) study using wider eligibility criteria that the HOPE study to assess the impact on AI induced arthralgia in breast cancer patients. Patients were randomly assigned, in a 3:1 ratio, to exercise intervention or usual care. Following randomization participants could choose from 3 types of exercise including group 1 (120-150 minutes per week of walking or running), group 2 (daily NIPPON HOSO KYOKAI: NHK broadcast exercise in Japan) and group 3 (going up the stairs- frequency, etc). The primary endpoint was the arthralgia change at 6 and 12 months, which was assessed using the BPI (Brief Pain Inventory). Secondary endpoints included the BPI according to the completion rate of exercise (70% and more or less than 70%), the BPI change of the patients with arthralgia (the patients who had arthralgia at the time they enrolled this study; BPI worst pain 3≤), the BPI of the each exercise group, the BPI according to the duration of AIs therapy (24 months and more or less than 24 months), the correlation between the BMI change and the BPI change, adherence of AIs and safety. 102 were randomly assigned to exercise intervention group (22 patients dropped out of this study) and 37 to usual care group (9 patients dropped out of this study).Trends for differentiations of pain interference at 12 months was detected between exercise intervention group and usual care group, but the differences did not reach statistical significance (p = .067). There was statistically better pain interference of the 70% and more exercise completion group than the usual care group at 12 months (-0.29±1.22 for exercise intervention group and 0.33±0.88 for usual care group, p= .002). The change of pain interference was statistically better for the exercise intervention group than the usual care group at 12 months (p= .017, -0.61±0.69 for exercise intervention group and 1.14±1.56 for usual care group). There was statistically significant difference of pain interference between group 1 exercise intervention group and the usual care group at 12 months (-0.14±0.68 for group 1 exercise intervention group and 0.33±0.88 for the usual care group, p= .009). Tendencies were detected in the AIs therapy less than 24 months group. Trends for the correlation between BPI and BMI were detected in worst pain at 6 month, pain severity at 6 month and pain interference at 12 month. There was a statistically significant difference of AIs adherence between the exercise intervention group (99%) and the usual care group (92%) (P=0.03). Exercise may be effective in improving and preventing AI-induced arthralgia. Citation Format: Tamaki K, Takaesu M, Nagamine S, Terukina S, Kamada Y, Uehara K, Takigami N, Arakaki M, Yamashiro K, Miyashita M, Ishida T, McNamara KM, Tamaki N, Sasano H. Final results of the randomized trial of exercise intervention vs. usual care for breast cancer patients with aromatase inhibitor to prevent and improve the aromatase inhibitor induced arthralgia [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-11-01.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2018
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2012
    In:  Cancer Research Vol. 72, No. 24_Supplement ( 2012-12-15), p. P1-06-02-P1-06-02
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 24_Supplement ( 2012-12-15), p. P1-06-02-P1-06-02
    Abstract: Vasohibin-1 is a recently identified negative feedback regulator of angiogenesis induced by VEGF-A and bFGF. Our previous study was the first study demonstrating the status of vasohibin-1 in human breast lesions, which indicates that vasohibin-1 is associated with neovascularization and may especially play important roles in the regulation of intratumoral angiogenesis in human breast cancer. In this study, we first evaluated mRNA expression of vasohibin-1 and CD31 in 39 Japanese emale breast carcinoma specimens including 22 invasive ductal arcinoma (IDC) and 17 ductal carcinoma in situ (DCIS) using a real-time quantitative RT-PCR (QRT-PCR) with LightCycler system. Table shows the primer sequences used in real-time PCR in this study. In addition, we also immunolocalized vasohibin-1 and CD31 and compared their immunoreactivity to nuclear grades and histological grades of 100 carcinoma cases (50 IDC and 50 DCIS). There were no statistically significant differences of CD31 mRNA expression and the number of CD31 positive vessels between DCIS and IDC (P = 0.250 and P = 0.191, respectively), whereas there was a statistically significant difference in vasohibin-1 mRNA expression and the number of vasohibin-1 positive vessels in DCIS and IDC (P = 0.022 and P & lt; 0.001, respectively). There was a significant positive correlation between vasohibin-1 mRNA level and Ki-67 labeling index in DCIS (r2 = 0.293, P & lt; 0.001). In addition, vasohibin-1 mRNA expression was correlated with high nuclear and histological grades in DCIS cases and a significant positive correlation was detected between the number of vasohibin-1 positive vessels and Ki-67 labeling index or nuclear grade or Van Nuys classification of carcinoma cells (P & lt;0.001, respectively). These results all indicate the possible correlation between aggressive biological features in DCIS including increased tumor cell proliferation and the status of neovascularization determined by vasohibin-1 immunoreactivity. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-06-02.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...